DDInter1082 DDInter1698
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan was granted FDA approval on 28 August 2020.
Somapacitan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Somapacitan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Somapacitan {u} may lead to a major life threatening interaction when taken with {v} Bexarotene
Somapacitan may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Dapsone
Somapacitan may lead to a major life threatening interaction when taken with Bexarotene